Compare the Best eClinical Systems for Biotech

Who this guide is for

This guide is for biotech founders, heads of clinical operations at emerging companies and small sponsor teams choosing eClinical technology for a first or second clinical programme. It is written for teams without a large IT or quality function, who need systems that are compliant, affordable and quick to deploy, and who must decide how much technology to own versus how much to leave to a CRO.

If you are looking for the best eClinical vendors for biotech, treat the vendor cards and table on this page as a starting point, not a verdict. The ranked cards show eClinical vendors across the whole category; the table narrows them to vendors whose profiles describe biotech sponsors as a fit. Neither can tell you how a system will work with your protocol, CRO and budget. Use the criteria below to decide what to ask.

What eClinical means for a biotech — and when you need to decide

eClinical covers the software used to run and oversee a trial: electronic data capture for case report forms, randomisation and trial supply management, electronic trial master files, clinical trial management systems, electronic patient-reported outcomes and eConsent. Large sponsors often run an enterprise suite across a portfolio. A biotech usually starts smaller, and many begin with whatever their CRO provides.

The decision points come earlier than many teams expect. The first is when you select a CRO, because its proposal will name systems and the contract will set who owns them. The second comes when a protocol needs something specific, such as patient-reported outcomes at home or adaptive randomisation. The third arrives when you plan a second study, a partnership or a financing round and need your data and documents in a form others can inspect. Making a deliberate choice at each point avoids expensive migrations later.

Building an eClinical stack in stages

Few biotechs need a full suite on day one. A staged approach keeps early costs proportionate while avoiding a forced migration later.

First-in-human and early Phase I

Studies are short, sites are few and the protocol may change quickly. Many sponsors rely on the CRO's or phase I unit's systems at this stage. The essentials are a compliant data capture system, a safety database and a trial master file you can access. Secure contract terms that give you the data in a standard format at the end.

Phase II and proof of concept

Studies grow in sites and countries, and endpoints may depend on patient-reported outcomes or central readings. This is often the point to choose a sponsor-owned data capture platform that can carry forward, and to decide whether randomisation and supply management sit on the same platform or with a specialist provider.

Pivotal and multinational studies

Confirmatory studies bring more countries, languages, integrations and inspection exposure. Check that the platform chosen earlier can scale, or plan a deliberate move between studies rather than during one. Standardised forms and data definitions from earlier studies make pooling and submission work easier.

How to evaluate an eClinical vendor as a biotech

Speed to first patient

For an emerging company, time to first patient often matters more than feature depth. Ask how long study build takes from final protocol to go-live, whether you can build yourselves with the vendor's tools, and what the vendor needs from you to keep to that timeline. Ask for references from sponsors of a similar size.

Total cost over your development plan

Entry prices vary widely, and so do pricing models: per study, per patient, per site or by subscription. Model the cost across your expected studies over several years, including build fees, change orders after protocol amendments, hosting, support and archive access. A cheap first study can lead to an expensive programme.

Compliance you can rely on with a small team

You will not have a large validation team, so the vendor's validation package and quality support matter. Ask how the system meets 21 CFR Part 11 and the EMA guideline on computerised systems and electronic data in clinical trials, what documentation you will receive, and how the vendor supports sponsor audits and regulatory inspections.

Working with your CRO

Ask whether your intended CRO already works in the system, how CRO staff would be given access, and who would build and maintain the study. Ask how the sponsor keeps direct access to data and reports when the CRO runs the system day to day, since ICH E6(R3) leaves oversight with the sponsor.

If you switch CRO between studies, a sponsor-owned platform lets the new CRO work in a system you already know, with your standard forms and reports intact. Ask the vendor how it has supported such handovers, how user access is transferred and how training for the incoming team is arranged.

Scaling from early to late phase

A system that suits a single Phase I study may struggle with a multinational Phase III. Ask about the scale of the studies currently running on the platform, how it handles multiple languages, sites and countries, and whether randomisation and supply management are built in or need a partner. Some profiles on this page state their own limits for large global programmes; take those statements seriously.

Support model and responsiveness

A small team cannot absorb long waits for help. Ask what support hours are offered for sponsors and sites, which languages are covered, whether you get a named contact, and how urgent issues during enrolment are escalated. Ask references how quickly problems were resolved during their first study.

Patient-facing and decentralised features

If your protocol includes home visits, remote consent or patient-reported outcomes, ask whether those features run on the same platform, how participants are supported and how licensed questionnaires are migrated from paper. Integrated patient tools reduce reconciliation work for a small team.

Safety data and pharmacovigilance links

Serious adverse events recorded in the trial database must reach the safety database and be reconciled before lock. Many biotechs outsource pharmacovigilance to a separate provider. Ask whether the eClinical platform can notify the safety team automatically when a serious event is entered, how reconciliation between the two databases is run, and who owns discrepancies. A clear, tested route for safety data protects participants and avoids late surprises at database lock.

Data ownership, export and exit

Investors, partners and acquirers will examine your data. Make sure the contract states that you own the data and that complete exports, including metadata and audit trails, are available in standard formats at a known cost. Ask how long archive access lasts after a study ends.

eClinical vendors for biotech at a glance

The table below lists eClinical vendors whose profiles name biotech sponsors in their stated fit. It is a short list by design: the wider category includes many systems that may also suit a biotech, which you can find in the guide to eClinical and EDC vendors.

The fields come from each vendor's Clinical Vendor Compare profile. A biotech fit in a profile is a statement about the intended customer, not evidence of performance. One of the records describes a technology-enabled CRO rather than a standalone software vendor. Confirm build timelines, pricing and phase coverage directly.

Vendor profiles

Medrio

Medrio's record positions it for emerging biotech sponsors running Phase I and Phase II trials who need fast, cost-effective data capture. It lists EDC, eConsent and ePRO on one platform, a self-service study builder and per-study pricing, from a United States headquarters. Biotech fit: strong alignment with early-phase speed and budget. Where to probe: its own record says it is less suited to large global Phase III programmes and has limited randomisation and supply management, so plan how you would scale.

Castor eClinical

Castor's record positions it for biotech sponsors, academic research groups and mid-size CROs wanting an affordable, fast-to-deploy EDC. It lists EDC with patient-facing ePRO, a drag-and-drop builder and per-patient pricing, from a headquarters in the Netherlands, covering Phase I to Phase IV. Biotech fit: relevant if patient-reported outcomes are central to your protocol. Where to probe: its record notes fewer large global Phase III deployments and limited trial management and supply modules.

Datatrak (TrialKit)

Datatrak's record positions TrialKit for biotechs wanting a flexible, easy-to-use EDC with built-in randomisation, and describes support for drug, biotech and device studies of small and medium scale. Biotech fit: built-in randomisation can reduce the number of systems a small team manages. Where to probe: confirm whether its randomisation covers your design, including stratification and supply needs, and what services sit alongside the software.

Vial (Vial CRO)

Vial's record describes a technology-native CRO that runs trials on its own technology platform, targeting biotech sponsors with end-to-end services across Phase I to Phase III in dermatology, ophthalmology, oncology and gastroenterology. Its record lists a young company and limited Phase III experience among its limitations. Biotech fit: relevant if you want CRO services and technology from one contract. Where to probe: ask how your data would be exported if you later moved to another CRO.

Mahalo Health

Mahalo Health's record describes an EDC and eClinical platform focused on decentralised trial features, aimed at small and mid-size biotechs, covering Phase I to Phase III in oncology, rare diseases, neurology and immunology. Its record notes a smaller market presence and limited enterprise experience. Biotech fit: relevant for decentralised designs. Where to probe: ask for live studies using its decentralised features and how sites and participants are supported.

Engagement and pricing models

Biotechs usually buy eClinical technology in one of three ways. They may use the CRO's systems, with costs inside the CRO budget. They may license a sponsor-owned platform per study or per patient and give the CRO access. Or they may engage a technology-enabled CRO that provides its own platform as part of its service. Some combine approaches, for example owning EDC while the CRO provides the trial master file.

The main cost drivers are build complexity, the number of modules, patient and site numbers, mid-study changes, integrations with labs and randomisation, and archive periods. Ask vendors to price your actual development plan, not just the first study, and agree who pays for change orders triggered by protocol amendments.

Questions to put in your RFP

• How long will study build take from our final protocol to go-live, and who does the build?
• What will our total cost be across our planned studies, including change orders and archive access?
• Which of the tools we need run on one platform, and which need partners or integrations?
• Does our intended CRO already work in your system, and how will its staff be given access?
• What validation documentation will we receive, and how do you support inspections?
• How does the system meet 21 CFR Part 11 and EU expectations for audit trails and access?
• How many countries, sites and languages do the broadest studies on your platform cover today?
• How are randomisation and drug supply handled for a design like ours?
• Which patient-facing features are live, and how are participants supported?
• In which formats can we export all data, metadata and audit trails, and at what cost?
• What happens to our data and access if we change CRO or are acquired?

Due-diligence red flags

• Build timelines that depend on unstated assumptions about your protocol or review speed.
• Low first-study pricing with steep per-patient or change-order fees.
• Validation documentation that is thin or available only after signature.
• No sponsor access to data and audit trails when the CRO runs the system.
• Decentralised features described from a roadmap rather than live studies.
• No credible path from early-phase use to a larger, multinational study.
• Restrictive or costly data export terms.
• No references from sponsors of similar size and stage.

Shortlist on Clinical Vendor Compare

Start in the vendor directory and filter for EDC and eClinical to see every listed system. Open profiles to check stated fit and limits, then place a few side by side on the compare page. If you are also choosing a CRO, read the guide to CROs for biotech and decide early who will own the systems. When your requirements are clear, use the sponsor RFP tool to brief vendors on your protocol, timeline and budget. If you have used any of these systems, please write a review so the next biotech has evidence to work from.